NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bundibugyo Ebolavirus
Benzinga Newsdesk 4 months ago
News
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II Clinical Trial of NV-387
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus to the Committee in Charge in the Democratic Republic of Congo (DRC).